ROARABLE // PRO
[FREE TERMINAL]
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

KNSA // Kiniksa Pharmaceuticals International plc Class A

DES <GO> NASDAQ CIK 0001730430 ↗
Health Care • Biotechnology: Pharmaceutical Preparations
$97.56 ▲ +2.38 (+2.50%)
MKT CAP: $7.67B • VOL: 1.38M
KNSA // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE
PRIOR: RQD 65/100 [C] (-1 PT) • UNCHANGED
ROARABLE C
RQD CONFIDENCE
64 / 100 -1D
5 X 20-PT QUANT PILLARS
E 0 D 35 C 59 B 70 A 86+
Roarable Hold — Fair / Balanced Risk-Reward
01 MASSIVE / SEC XBRL
Forensic Fundamentals
15 / 20
SOLID
FCF +200% vs NI +200% • ROIC-WACC +0.1% • Z 24.45
02 OPRA GEX + SEC 13F
Whale & Options Flow
[LOCKED] FLAGGED
UNLOCK BELOW TO REVEAL
03 SEC FORM 4 (90D)
Insider Conviction
[LOCKED] FLAGGED
UNLOCK BELOW TO REVEAL
04 FRED 90D r-MATRIX
Macro Regime Fit
14 / 20
SOLID
TAILWIND • r(10Y)=+0.00 (+23bp) • r(OAS)=+0.00
05 10-K REDLINE AUDIT
Forensic 10-K Risk
13 / 20
SOLID
20 BASE - 7 DEDUCT • 0 CRIT / 0 MED • STABLE
ALERT

Why did KNSA's Whale & Options Flow & Insider Conviction sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever KNSA is Upgraded or Downgraded.
SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON KNSA)
ALL MARKET ANOMALIES <SIG>
▼ BEARISH // F-RATED EARNINGS MIRAGE // ACCRUAL WATCHSIFTER 02 // ACCRUAL & RECEIVABLES FORENSICS
SEVERITY: 81/100 Z-SCORE: +2.24σ

KNSA Accounting Gap: Net Income (+220%) Outpaced OCF (+220%) With +83.9% Working-Capital Build

CASH CONVERSION GAP
+0.0% (NI vs OCF)
RECEIVABLES / WC BLOAT
+83.9% VS REV
60D C-SUITE FORM 4 SALES
0 OPEN-MKT DUMPS
[GEEK DESK FORENSIC NOTE // SEC XBRL × FORM 4 CROSS-CHECK]
SEC EDGAR XBRL CompanyFacts10-K/10-Q Working Capital ScheduleSEC Form 4 Executive Sales

SEC EDGAR XBRL triangulation on Kiniksa Pharmaceuticals International plc Class A (KNSA) exposes a +0.0% Cash Conversion Gap as YoY Net Income growth (+220.0%) diverged from Operating Cash Flow growth (+220.0%). Non-cash current assets and receivables expanded +83.9% relative to top-line revenue growth. Monitor upcoming 10-Q cash realization closely for accrual mean-reversion.

KNSA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +71.51%▲ ASCENDING CHANNEL
2026-10-30O $97.40H $98.48L $91.25C $92.24VOL 1.32M
RES: $111.7SUP: $71.28SMA50: $79.16SMA200: $60.21
$102.6$85.67$68.79$51.91$35.03RES $111.7SUP $71.28$92.242026-04-302026-06-152026-07-312026-09-162026-10-30
KNSA // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE
UNDERWEIGHT CONVICTION: 42/100
BEAR 0
100 BULL

Kiniksa Pharmaceuticals International plc Class A (KNSA) exhibits 88.5% gross margins and 9.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 95.0x enterprise multiple and 7.3% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)
01. Operating Leverage & Capital Efficiency Moat

Sustained 88.5% gross profitability converts into 11.4% operating margin and 9.9% ROIC, outpacing sector cost of capital.

ROIC: 9.9% // GM: 88.5%
02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of +60.1% paired with 1.78% free cash flow yield supports self-funded R&D and capital return.

REV YOY: +60.1% // FCF YLD: 1.78%
03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 24.45 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.

ALTMAN Z: 24.45 // F-SCORE: 9/9
▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)
01. Multiple Compression & Duration Sensitivity

Trading at 129.9x trailing P/E (109.1x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 129.9x // EV/EBITDA: 95.0x
02. Options Skew & Event Volatility Risk

Options market prices a ±7.3% implied move with a 0.72 put/call ratio around $96.00 max pain.

IMPL MOVE: ±7.3% // P/C: 0.72
03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 8.7% net margins.

NET MARGIN: 8.7% // D/E: 0.15x
KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 109.1x forward consensus, and institutional 13F positioning.
MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.11).
FORM 4 & 13F FLOW OPEN OWN <GO>
FILER SIDE $ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>
UNUSUAL OPTIONS TAPE OPEN OPT <GO>
STRIKE / EXP TYPE PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>
KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>
TRAILING P/E 129.9x
FORWARD P/E 109.1x
EV / EBITDA 95.0x
FCF YIELD 1.78%
GROSS MARGIN 88.5%
OPERATING MARGIN 11.4%
NET MARGIN 8.7%
ROIC % 9.9%
REV GROWTH YOY +60.1%
DILUTED EPS TTM $0.75
DEBT / EQUITY 0.15x
DIVIDEND YIELD 0.00%
RSI-14 MOMENTUM 63.0
5Y EQUITY BETA 1.11
FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>
MACRO CORRELATION CALIBRATION ACTIVE BELOW.
FRED MACRO REGIME STRESS-TEST SIMULATOR // KNSAPEARSON R VARIANCE ENGINE
01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO
02 // POSITION NOTIONAL EXPOSURE
HEADLINE STRESS SCORE
75/100SEVERE DRAWDOWN PRESSURE
PRIMARY FACTOR EXPOSURE
DFII10 // -0.61 r
Latest: 2.08%
EST. DIRECTIONAL MOVE
-8.50%
Implied Px: $89.27
EST. DOLLAR VARIANCE
-$4,248
On $50,000 Notional
[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for KNSA & activate live FRED threshold breach alerts.
HEAD-TO-HEAD PEER COMPARISONS COMP <GO>
KNSA VS LLY
MARGINS ROIC VALUATION
KNSA VS JNJ
MARGINS ROIC VALUATION
KNSA VS ABBV
MARGINS ROIC VALUATION
KNSA VS UNH
MARGINS ROIC VALUATION